Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TTK | P33981 | 5/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.53 |
| ▸ | GAA | P10253 | 2/20 | 0.53 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.53 |
| ▸ | CDK2 | P24941 | 2/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | IDO1 | P14902 | 2/20 | 0.46 |
| ▸ | ALPL | P05186 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.46 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | YTHDC1 | Q96MU7 | 1/20 | 0.41 |
| ▸ | AURKA | O14965 | 1/20 | 0.41 |
| ▸ | STAT3 | P40763 | 1/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31443036 | 1.00 | TTK (0.54) | TTKKDM4EGAAPDPK1CYP3A4 | |
| SCHEMBL329157 | 0.82 | KDM4E (0.50) | TTKKDM4EGAAPDPK1CYP3A4 | |
| SCHEMBL5097449 | 0.81 | KDM4E (0.48) | TTKKDM4EGAAPDPK1CYP3A4 | |
| SCHEMBL30464803 | 0.81 | KDM4E (0.48) | TTKKDM4EGAAPDPK1CYP3A4 | |
| SCHEMBL29769111 | 0.81 | KDM4E (0.48) | TTKKDM4EGAAPDPK1CYP3A4 | |
| SCHEMBL6168435 | 0.81 | KDM4E (0.48) | TTKKDM4EGAAPDPK1CYP3A4 | |
| SCHEMBL10608557 | 0.81 | CYP1A2 (0.50) | TTKKDM4EGAAPDPK1CYP3A4 | |
| SCHEMBL30437389 | 0.80 | KDM4E (0.48) | TTKKDM4EGAAPDPK1CYP3A4 | |
| SCHEMBL8249449 | 0.78 | CYP1A2 (0.47) | TTKKDM4EGAAPDPK1CYP3A4 | |
| SCHEMBL1545527 | 0.78 | TTK (0.48) | TTKKDM4EGAAPDPK1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 88 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2019162974-A1 | METHOD TO DIAGNOSE CANCER PROGRESSION BASED ON PROKARYOTIC BIOMARKERS AND MOLECULES FOR USE IN THE TREATMENT OF CANCER PROGRESSION | ULISSE BIOMED S.R.L. (IT) | 2019-08-29 | — | — | WO | claimed |
| US-20090005417-A1 | Substituted Indazolyl Sulfonamide and 2,3-Dihydro-Indolyl Sulfonamide Compounds, their Preparation and Use in Medicaments | LABORATORIOS DEL DR. ESTEVE S.A. (ES) | 2009-01-01 | — | — | US | claimed |
| CN-101133034-A | Substituted indazolyl sulfonamide and 2,3-dihydro-indolyl sulfonamide compounds, their preparation and use in medicaments | ESTEVE LABOR DR (ES) | 2008-02-27 | — | — | CN | claimed |
| EP-1869002-A1 | SUBSTITUTED INDAZOLYL SULFONAMIDE AND 2,3-DIHYDRO-INDOLYL SULFONAMIDE COMPOUNDS, THEIR PREPARATION AND USE IN MEDICAMENTS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2007-12-26 | — | — | EP | claimed |
| WO-2006069809-A1 | SUBSTITUTED INDAZOLYL SULFONAMIDE AND 2,3-DIHYDRO-INDOLYL SULFONAMIDE COMPOUNDS, THEIR PREPARATION AND USE IN MEDICAMENTS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2006-07-06 | — | — | WO | claimed |
| EP-1676841-A1 | Substitited indazolyl sulfonamide and 2,3-dihydro-indolyl sulfonamide compounds, their prepartion and use in medicaments | Esteve Laboratorios Dr. Esteve S.A. (ES) | 2006-07-05 | — | — | EP | claimed |
| CN-1048246-C | Indazolesulfonylurea derivative, use thereof, and intermediate for production thereof | KUMIAI CHEMICAL INDUSTRY CO (JP) | 2000-01-12 | — | — | CN | claimed |
| EP-0657450-B1 | INDAZOLESULFONYLUREA DERIVATIVE, USE THEREOF, AND INTERMEDIATE FOR PRODUCTION THEREOF | KUMIAI CHEMICAL INDUSTRY CO (JP) | 1998-09-09 | — | — | EP | claimed |
| US-5763616-A | HERBICIDES | KUMIAI CHEMICAL INDUSTRY CO., LTD. (JP) | 1998-06-09 | — | — | US | claimed |
| CN-1110478-A | Indazolesulfonylurea derivative, use thereof, and intermediate for production thereof | KUMIAI CHEMICAL INDUSTRY CO (JP) | 1995-10-18 | — | — | CN | claimed |
| EP-0657450-A1 | INDAZOLESULFONYLUREA DERIVATIVE, USE THEREOF, AND INTERMEDIATE FOR PRODUCTION THEREOF | KumaiI Chemical Industry Co., Ltd. (JP) | 1995-06-14 | — | — | EP | claimed |
| EP-3676255-B1 | THERAPEUTIC INDAZOLES | RUTGERS THE STATE UNIV UNIV OF NEW JERSEY (US) | 2025-04-16 | — | — | EP | disclosed |
| EP-4499609-A1 | INHIBITORS OF THE MYST FAMILY OF LYSINE ACETYL TRANSFERASES | Isosterix, Inc. (US) | 2025-02-05 | — | — | EP | disclosed |
| CN-119301096-A | Inhibitors of MYST family lysine acetyltransferase | 伊索斯泰里克斯公司 | 2025-01-10 | — | — | CN | disclosed |
| WO-2023192817-A9 | INHIBITORS OF THE MYST FAMILY OF LYSINE ACETYL TRANSFERASES | Isosterix, Inc. (US) | 2024-10-03 | — | — | WO | disclosed |
| US-5763616-A | HERBICIDES | KUMIAI CHEMICAL INDUSTRY CO., LTD. (JP) | 1998-06-09 | — | — | US | disclosed |
| US-5670452-A | PREEMERGENCE HERBICIDES | KUMIAI CHEMICAL INDUSTRY CO., LTD. (JP) | 1997-09-23 | — | — | US | disclosed |
| US-5534481-A | Indazolesulfonylurea derivative, its use and intermediate for its production | KUMIAI CHEMICAL INDUSTRY CO., LTD. (JP) | 1996-07-09 | — | — | US | disclosed |
| CN-1110478-A | Indazolesulfonylurea derivative, use thereof, and intermediate for production thereof | KUMIAI CHEMICAL INDUSTRY CO (JP) | 1995-10-18 | — | — | CN | disclosed |
| EP-0657450-A1 | INDAZOLESULFONYLUREA DERIVATIVE, USE THEREOF, AND INTERMEDIATE FOR PRODUCTION THEREOF | KumaiI Chemical Industry Co., Ltd. (JP) | 1995-06-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090005417-A1 | Substituted Indazolyl Sulfonamide and 2,3-Dihydro-Indolyl Sulfonamide Compounds, their Preparation and Use in Medicaments | HTR6, TPH2, HTR5A | TTK 4307/4885KDM4E 4228/4885GAA 2558/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.